JDD Corner

JDD Buzz Series | Diversity in Melasma Clinical Trials
melasmaUnderrepresentation of patients with skin of color in clinical trials is an issue in medical research, including in research about dermatological conditions. A study in the January Journal of Drugs in Dermatology looked at the diversity of patients enrolled in melasma clinical trials to determine if there are any disparities in representation. I interviewed author Jared Jagdeo, MD, MS, associat …
melasma
Co-occurring Melanoma in an Active Area of Vitiligo in Skin of Color
vitiligo The association between vitiligo and melanoma is complex. While the incidence of vitiligo in patients with melanoma is higher, the risk for the reverse, ie, the development of melanoma in a patient with vitiligo, is thought to be decreased. This report presents a case of melanoma developing on a non-sun-exposed site in a patient with skin of color and untreated vitiligo. It emphasizes the need …
vitiligo
JDD January 2025 Editor’s Picks | Special Focus: Aesthetic Treatments
Welcome to the first issue of the Journal of Drugs in Dermatology for 2025! This issues focuses on the exciting advancements in aesthetic treatments, with editor’s picks that delve into cutting-edge topics shaping dermatology today. From the role of exosomes in cosmetic dermatology to expert insights on managing neuromodulator complications, this issue offers invaluable guidance for pr …
JDD Buzz Series | Metformin’s Potential Chemopreventive Effect
metforminA commonly used diabetes medication may help prevent non-melanoma skin cancer. A study in the December Journal of Drugs in Dermatology analyzed whether metformin exposure is associated with a reduced risk of non-melanoma skin cancer. The study also stratified findings by race/ethnicity, which makes it unique among similar research studies. I interviewed author Tiffany Jow Libby, MD, FAAD, FACMS …
metformin
Hyperpigmented Macules and Patches on the Face: Exogenous Ochronosis or Lichen Planus Pigmentosus?
Exogenous Ochronosis (EO)JDD authors Deepika Narayanan, MD and Stephen K. Tyring, MD, PhD, MBA present a case of a patient with a 10-year history of blue-black macules and patches on the face and an associated history of skin- lightening cream usage. The skin lightening cream contained hydroquinone, which is often associated with exogenous ochronosis (EO). Interestingly, the biopsy did not show characteristic findings of …
Exogenous Ochronosis (EO)